Promoter holding
64.27%
SP
Sms Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Sms Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress si…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sms Pharmaceuticals — 360° Intelligence Report
Generated from MCA filings & public records87/100
Trust Score
Low Risk
Sms Pharmaceuticals is assessed as Low Risk with a Trust Score of 87/100. Sms Pharmaceuticals is an active public limited indian non-government company incorporated in 1987, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 23 Jul 2026 from the latest processed filings. Sms Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
- Moderate gearing (D/E 38%).
- Profitable - internal accruals available.
- Externally credit-rated (A).
Charges position: 12 open (600.28 cr) · 51 satisfied (640.70 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 7 | 48.0 cr |
| State Bank Of India | 5 | 48.0 cr |
| Idbi Bank Limited | 4 | 48.0 cr |
| Export Import Bank Of India | 6 | 48.0 cr |
| Export-Import Bank Of India | 5 | 48.0 cr |
| Yes Bank Limited | 1 | 48.0 cr |
Compliance Score: 80/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- 3 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SRINIVAS SARVEPALLI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VAMSI KRISHNA POTLURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| LAKSHMI NARAYANA TAMMINEEDI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRAVAN KUDARAVALLI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMESH BABU POTLURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TRILOK POTLURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHANTI SREE BOLLENI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mr. Thirumalesh Tumma | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Sunkara Venkata Satya Shiva Prasad | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GANGAVARAPU SURESH KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
-
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Chemo Sms Enterprises Sl | Joint Ventures | 74.00% |
| Vkt Pharma Private Limited | Associate Company | 74.00% |
Key managerial personnel: VAMSI KRISHNA POTLURI (Whole-time director) · LAKSHMI NARAYANA TAMMINEEDI (CFO) · RAMESH BABU POTLURI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 80
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 38+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 director exits within 2 years.
12 open charge(s) registered - assets are encumbered.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment84/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 12 open charge(s) of 600.28 cr already registered.
- Compliance record supports lending.
Investor view87/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events28 Oct 2025
Charge satisfied
Others
22 Oct 2025
Charge created
Axis Bank Limited - 34.15 cr
29 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Nov 2024
Charge satisfied
Others
29 Sep 2024
Director ceased
TRILOK POTLURI
Director ceased
SHANTI SREE BOLLENI
Director ceased
Sunkara Venkata Satya Shiva Prasad
Director ceased
GANGAVARAPU SURESH KUMAR
12 Aug 2024
Director appointed
TRILOK POTLURI (Director)
Director appointed
SHANTI SREE BOLLENI (Director)
Director appointed
Sunkara Venkata Satya Shiva Prasad (Director)
Director appointed
GANGAVARAPU SURESH KUMAR (Director)
14 Feb 2024
Charge created
Others - 100.00 cr
02 Nov 2023
Charge created
Others - 130.00 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
10 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of A from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Kokuyocamlin | L24223MH1946PLC005434 | Mumbai, Maharashtra, India |
| Samilabs | U68100KA1991PLC011880 | Bangalore, Karnataka, India |
| Windlas | L74899UR2001PLC033407 | Dehradun, Uttarakhand, India |
| Neogenchem | L24200MH1989PLC050919 | Thane, Maharashtra, India |
| Provimi | U24111KA1983PTC005213 | Bangalore, Karnataka, India |
| Hygienic Research Institute | U24247MH2002PTC135338 | Mumbai, Maharashtra, India |
| Virupaksha | U24110TG1997PLC028281 | Hyderabad, Telangana, India |
| Forace Speciality Chem Private Limited | U36999UR2017PTC007621 | Haridwar, Uttarakhand, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sms Pharmaceuticals before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sms Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Sms Pharmaceuticals - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Sms Pharmaceuticals pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Sms Pharmaceuticals - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sms Pharmaceuticals an active company?
Sms Pharmaceuticals has MCA status “Active” with a compliance score of 80/100 (Low Risk).
Is Sms Pharmaceuticals financially healthy?
Sms Pharmaceuticals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Sms Pharmaceuticals?
Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sms Pharmaceuticals?
Promoters hold a majority stake - exact percentages are in the full report. 10 active director(s) are on record.
Does Sms Pharmaceuticals have loans or charges against its assets?
12 open charge(s) are registered against its assets, and 51 earlier charge(s) stand satisfied.
Is Sms Pharmaceuticals up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 80/100 (Low Risk).
Is it risky to lend to Sms Pharmaceuticals?
Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
